News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
706,766 Results
Type
Article (41905)
Company Profile (435)
Press Release (664426)
Section
Business (208548)
Career Advice (2016)
Deals (35984)
Drug Delivery (97)
Drug Development (83441)
Employer Resources (170)
FDA (16371)
Job Trends (15063)
News (352396)
Policy (33013)
Tag
Academia (2620)
Alliances (50817)
Alzheimer's disease (1345)
Approvals (16328)
Artificial intelligence (199)
Bankruptcy (364)
Best Places to Work (11828)
Biotechnology (329)
Breast cancer (221)
Cancer (1651)
Cardiovascular disease (132)
Career advice (1681)
CAR-T (118)
Cell therapy (347)
Clinical research (66857)
Collaboration (650)
Compensation (337)
COVID-19 (2616)
C-suite (151)
Data (1546)
Diabetes (202)
Diagnostics (6298)
Earnings (86384)
Employer resources (147)
Events (114082)
Executive appointments (546)
FDA (17215)
Funding (585)
Gene therapy (244)
GLP-1 (674)
Government (4439)
Healthcare (19073)
Infectious disease (2719)
Inflammatory bowel disease (121)
Interviews (309)
IPO (16706)
Job creations (3697)
Job search strategy (1431)
Layoffs (459)
Legal (7955)
Lung cancer (243)
Manufacturing (232)
Medical device (13395)
Medtech (13400)
Mergers & acquisitions (19587)
Metabolic disorders (550)
Neuroscience (1761)
NextGen: Class of 2025 (6749)
Non-profit (4544)
Northern California (1970)
Obesity (313)
Opinion (209)
Patents (139)
People (58111)
Phase I (21000)
Phase II (29512)
Phase III (21805)
Pipeline (665)
Postmarket research (2600)
Preclinical (8954)
Radiopharmaceuticals (256)
Rare diseases (324)
Real estate (6002)
Regulatory (22298)
Research institute (2406)
Resumes & cover letters (351)
Southern California (1714)
Startups (3753)
United States (17913)
Vaccines (617)
Weight loss (219)
Date
Today (160)
Last 7 days (616)
Last 30 days (2899)
Last 365 days (35722)
2025 (3043)
2024 (36299)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54923)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (733)
Arizona (214)
Asia (38852)
Australia (6465)
California (4571)
Canada (1631)
China (380)
Colorado (206)
Connecticut (222)
Europe (84751)
Florida (649)
Georgia (156)
Illinois (456)
Indiana (252)
Maryland (723)
Massachusetts (3579)
Michigan (192)
Minnesota (331)
New Jersey (1286)
New York (1299)
North Carolina (867)
Northern California (1970)
Ohio (166)
Pennsylvania (1052)
South America (1107)
Southern California (1714)
Texas (664)
Utah (133)
Washington State (457)
706,766 Results for "nikang therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma
January 21, 2025
·
3 min read
Drug Development
NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.
April 15, 2024
·
3 min read
Business
NiKang Therapeutics Appoints Joanne Lager, M.D., as Chief Medical Officer
NiKang Therapeutics Inc. today announced the appointment of Joanne (Jo) Lager, M.D., as Chief Medical Officer (CMO), reporting to Zhenhai Gao, Ph.D., Co-founder, President and Chief Executive Officer (CEO) of NiKang.
January 4, 2024
·
2 min read
BioCapital
NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024
NiKang Therapeutics Inc. announced today the unveiling of NKT3447 at the American Association for Cancer Research (AACR) Annual Meeting 2024. NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDK.
April 5, 2024
·
3 min read
News
NiKang Therapeutics® Presents Discovery of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 PROTAC Degrader for Cancer Therapy, at the EORTC-NCI-AACR Symposium 2024
October 24, 2024
·
3 min read
Business
NiKang Therapeutics Enters into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in first-line treatment of unresectable/advanced hepatocellular carcinoma (HCC).
December 8, 2023
·
2 min read
Business
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
NiKang Therapeutics Inc. today announced that Dr. Anne Borgman has been appointed to the company’s Board of Directors.
January 18, 2023
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 23, 2025
·
5 min read
Press Releases
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
February 4, 2025
·
7 min read
1 of 70,677
Next
